| This study was aimed at exploring the mechanisms of Warming Yang to Dispelling Coldness and Invigorating Qi and Nourishing Blood (WYDCIQNB) decoction on treating malignant tumor and observing the clinical effect on non-small-cell lung cancer and. It was composed of following trials.1. Experiments on the Anti-tumor Effects of Warming Yang to Dispelling Coldness and Invigorating Qi and Nourishing Blood decoction Here, cells of S180 sarcoma and EAC cell line were transplanted to Kunming line mice respectively to produce transplanted tumors among the animals. Following transplantation of tumor cells, the animals were fed with the solution of WYDCIQNB herb. In this experiment, investigated in vivo were the effect of tumor-inhibiting on mice with transplanted tumors of S180 sarcoma and the effect of survival duration-extending on mice with ascites due to transplanted EAC.2. Experiments on the Effects of Warming Yang to Dispelling Coldness and Invigorating Qi and Nourishing Blood on the Dendritic Cell In these experiments, the EAC mouse was produced, giving the solution of WYDCIQNB, separated the mononuclearcell from the ascites of mice with EAC transplated. Investigated the CD11c, CD80 and both of them positive cell by flow cytometry. The marow cell were get from mouse, culture the cells in media with WYDCIQNB herb solution and rm GM-CSF, rm IL-4. Observe the cells in different time, Investigated the CD11c, CD80 and both of them positive cell by flow cytometry. The peripheral blood were get from the NSCLC patients before and after treatment. Investigated the quantitation of DC and ratio of DC/PBMC(peripheral blood mononuclear cell) by flow cytometry.3. Experiments on the Effects of WYDCIQNB on the Levels of Cytokines Enzyme-linked immunosorbent assay (ELISA) was taken to determine the levels of IL-4, IL-12, INF-γin the ascites of mice with EAC transplated after taken WYDCIQNB solution. The same method to determine the level of IL-12 in media of culture marow-derived DC with WYDCIQNB solution.4. Observation the Effects of WYDCIQNB on the Killing Activity of Cytotoxic T-lymphocyte (CTL) mediated by DC Here, get the marow-derived DC which cultured by the media with WYDCIQNB solution. Co-cultured with T cells separated and culture from mouse spleen at the ratio of 1:50 for 3 days. Separated the tumor cell from the escites of mice with EAC transplated. Distributed at an effector-target raio of 1:20 for DC, T cell to tumor cell. Investigating the killing activity of T cell by MTT.5. Clinical Trial to investigate the Therapeutic Effect of WYDCIQNB on Patients with Non-small-cell Lung Cancer In this trial, two groups of cases were included, one group given with combined WYDCIQNB therapy as treating one and the other with chemotherapy only as controlling one. Then, the therapeutic effects of different therapies were compared among these cases to see the clinical response to this medicine. From the experiments done as stated as above, the results obtained were shown as follows.1. Tumor-Inhibiting Effects of WYDCIQNB These experiments showed that the tumor-inhibiting rates for the animals with the cells of S180 sarcoma transplanted were 47.22% and 45.78%, the survival duration-extending rates were 46.56% and 36.69% for those with EAC cells transplanted respectively, when they were treated with high and low dose WYDCIQNB herb. There were statistically significant differences present among them when compared with that of other groups (P<0.05).2. The Effects of WYDCIQNB on the Dendritic These experiments showed that in the cells of separated from escited of mice with EAC transplanted, in the treating group taken orally by WYDCIQNB herb were significantly higher than modelling and chemotherapy group(P<0.05). On the other hand, The ratio of CD11c positive, CD80 postive, both CD11c and CD80 positive in the marow cell cultured with WYDCIQNB were significantly higher than blank contrl group(P<0.05).3. The Effect of WYDCIQNB on the Levels of Cytokines The level of IL-12, INF-γin escites of mice with EAC transplanted in treating group with taken orally by WYDCIQNB herb were significantly higher than modelling and chemotherapy group(P<0.01). In the same time, the level of IL-4 in treating group were significantly lower(P<0.01). On the other hand, The level of IL-12 in culture media with WYDCIQNB solution is significantly higher than blank control group(P<0.05).4. The Effects of WYDCIQNB on the Killing Activity of Cytotoxic T-lymphocyte (CTL) mediated by DC The killing activity of CTL mediated by DC which cultured with WYDCIQNB solution were significantly higher than blank control group(P<0.05).5. Clinical Therapeutic Effect of WYDCIQNB on Patients with Non-small- cell Lung Cancer The ratio of lymph node metastasis after 2 months of treating group was 4.71%, was significantly lower than that of controlling one treated with chemotherapy only(P<0.05). Furthermore, the effect of main symptoms were also significantly improved among the patients of treating group; with a very significant difference (P<0.05) when compared with that of controlling one.Based on an analysis on these results, following conclusions could be made.1. WYDCIQNB holds very strong inhibitory effect on transplanted tumors of S180 sarcoma as tested in vivo and significantly extending effect on the survival duration of animals with transplanted EAC cells in situ.2. WYDCIQNB can improve the expression of CD11c, a specific surface antigen of DC, and CD80, a kind of costimulatory molecules, in vitro and vivo. It's means WYDCIQNB can improve the number of DC and the ratio of mature.3. WYDCIQNB can elevate the level of IL-12, IFN-γ,the cytokine of Th1, and decrease the level of IL-4,the cytokine of Th2, in the ascites of mice with EAC transplanted. These effects are able to improve the local immunologic microenviroment of cases with tumor and benefial for Th1/Th2 shifting in the direction towards Th1. The mechanism maybe has some relationship with that WYDCIQNB can improve the number of DC and the ratio of mature.4. WYDCIQNB can improve the killing activity of CTL mediated which by DC. 5. WYDCIQNB can decrease the ratio of lymph node metastasis, improve effect on the main symptoms seen among the patients with NSCLC when it combined with chemotherapy.
|
PDF Full Text Request